Assigment .Apa seven . All instructions attached.

Pino 1

Eniusky Pino

Florida National University

Professor Yvette De la Vega

Advanced Writing and Research-DBX-DL01

19 July 2026

Continuous Glucose Monitoring in Type 2 Diabetes Care

For many adults with type 2 diabetes, glucose monitoring typically involves stopping several times a day to prick a finger and jotting down a single number. Continuous glucose monitoring (CGM) modifies that experience by employing a small sensor worn on the body to measure glucose in the fluid under the skin all day and all night. The sensor delivers information to a receiver or smartphone, allowing patients and clinicians to observe patterns, trends and alerts rather than isolated measurements. CGM was first used mostly by people with type 1 diabetes or those on intensive insulin therapy, but emerging data has broadened its relevance in general care for adults with type 2 diabetes, including some who use basal insulin exclusively or noninsulin medicines. This is especially important for family nurse practitioners, as managing diabetes includes appropriate medication adjustments, patient education, lifestyle counseling, and prevention of complications. Continuous glucose monitoring is reshaping type 2 diabetes care by improving glycemic control, strengthening patient self-management and primary care collaboration, and offering long-term economic value despite ongoing barriers involving cost, training, insurance coverage, and equitable access.

First, CGM can enhance control of blood sugar because it gives a fuller view of glucose variations than occasional finger-stick tests. A standard meter tells you what your glucose level is at a single point in time, whereas CGM shows you the direction and speed of change, time spent in range, bouts of hyperglycemia and probable hypoglycemia. The MOBILE randomized clinical trial included people with poorly controlled type 2 diabetes receiving basal insulin therapy in primary care settings. Investigators found that CGM was associated with “significantly lower HbA1c levels at 8 months” compared to blood glucose meter monitoring (Martens et al. ). This finding is noteworthy because even a moderate drop in HbA1c may assist clinicians determine whether medication, nutrition or activity strategies are working. The wider research backs up the trial findings. In 2024 a comprehensive review and meta-analysis of twelve randomized trials indicated that CGM lowered HbA1c by an average of 0.31 percentage points and increased time in range by more than six percentage points. The authors concluded that “CGM use compared with SMBG is associated with improvements in glycaemic control” (Jancev et al. . The device also picks up overnight and post-meal patterns that patients may not see with planned testing. For the family nurse practitioner, these trends can help to make safer drug modifications and more targeted counseling. CGM data should not replace a clinical assessment. Sensor accuracy, symptoms, medications and the individual’s treatment plan still need to be addressed.

CGM can also enhance self-management and promote collaboration between patients and primary care teams. With diabetes, people have to make daily decisions regarding food, exercise, medicine, sleep and stress, but many patients cannot clearly relate these actions to subsequent glucose results. They get instant feedback and can see how a meal, an exercise or a missing medication alters the glucose curve.” In the DISCO GM randomized crossover study, people with complex type 2 diabetes reported improvement in self-management scores, quality of life, HbA1c and time in range. The researchers found that “the introduction of CGM can significantly improve diabetes self-management behaviour” (Parsons et al.). This instructional impact can make an abstract guideline, like limiting refined carbs, visible and personal. CGM also can increase the efficiency of office visits since the practitioner, and the patient can study the same data and establish specific goals. A 2025 pilot project trained primary care doctors to read CGMs using pharmacists and diabetes educators to help with sensor implantation, teaching and follow-up. Increased time in range significantly and average HbA1c fell from 9.68% to 7.31%. The authors concluded that using CGM in primary care was “feasible and effective using a multidisciplinary approach” (Zadel et al.). These data show that effective implementation is a function not just of acquiring the device, but also of educating patients how to respond to the information and preparing doctors to read the standardized reports . Without education, too many alarms or strange graphs might produce confusion instead of confidence.

Finally, the long-term benefits of CGM should be weighed against the practical and ethical constraints of the device. There is an ongoing cost for sensors and transmitters, and coverage regulations may range depending on insurance plan, prescription regimen and documentation needed. Furthermore, patients may not own a compatible smartphone, have dependable internet access, computer literacy, or the ability to update sensors accurately. But economic research implies that higher monitoring expenses may be compensated by better control and fewer issues. A 2024 U.S. microsimulation of persons with type 2 diabetes on basal insulin found CGM “offered more QALYs … at a lower cost” over 10 years than finger-stick monitoring (Frank et al.). The model estimated savings from decreased severe hypoglycemia events, diabetic ketoacidosis episodes, and long-term cardiovascular and renal consequences. This was a simulation and not a clinical experiment, thus the conclusions are based on the assumptions that were built into the model and should be read with caution. Another concern is access. A evaluation in 2026 found “ongoing inequities by age, race and ethnicity, insurance coverage and care setting” (Villanueva et al.). These disparities may deny people with the greatest illness burden access to technology. Primary care organizations consequently need clear eligibility processes, staff training, appropriate language education, technical support, privacy measures and plans for patients who cannot afford sensors on an ongoing basis. CGM can be a high-value improvement, but without healthcare systems addressing pricing and digital access its advantages will be unequal.

To conclude, continuous glucose monitoring represents an important improvement in the management of type 2 diabetes. Research demonstrates it can enhance HbA1c and time in range, assist patients understand how their daily actions impact glucose, and encourage more focused engagement with family nurse practitioners and interdisciplinary primary care teams. Economic models also imply that avoiding acute events and long-term problems may offset some of the expense of the technology. At the same time, CGM is not necessarily helpful for every patient. Insurance limits, device costs, data interpretation, alarm fatigue, and inequitable access may limit its utility. The most appropriate method is therefore to combine the device with tailored education, clinical follow-up and equal coverage policies. As CGMs become more popular in primary care, family nurse practitioners will be key in identifying who may benefit, training patients how to utilize the information securely, and ensuring that technology improves treatment rather than widens existing gaps.

Works Cited

Frank, Jerry, et al. “Continuous Glucose Monitoring for Self-Management of Diabetes in People Living with Type 2 Diabetes Mellitus on Basal Insulin Therapy: A Microsimulation Model and Cost-Effectiveness Analysis from a US Perspective with Relevance to Medicaid.” Journal of Managed Care & Specialty Pharmacy, vol. 30, no. 9, 2024, pp. 917–928. https://doi.org/10.18553/jmcp.2024.24025.

Jancev, Milena, et al. “Continuous Glucose Monitoring in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.” Diabetologia, vol. 67, no. 5, 2024, pp. 798–810. https://doi.org/10.1007/s00125-024-06107-6.

Martens, Thomas W., et al. “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial.” JAMA, vol. 325, no. 22, 2021, pp. 2262–2272. https://doi.org/10.1001/jama.2021.7444.

Parsons, Sharon N., et al. “Does the Short-Term Use of Continuous Glucose Monitoring Enhance Diabetes Self-Management Behaviour in Type 2 Diabetes? The DISCO GM Study: A Randomised, Controlled Cross-Over Study.” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 19, no. 7, 2025, article 103283. https://doi.org/10.1016/j.dsx.2025.103283.

Villanueva, Giuliana Perini, et al. “Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-Effectiveness.” Current Diabetes Reports, vol. 26, no. 1, 2026, article 19. https://doi.org/10.1007/s11892-026-01631-8.

Zadel, Alyssa H., et al. “Continuous Glucose Monitoring in Primary Care: Multidisciplinary Pilot Implementation Study.” JMIR Diabetes, vol. 10, 2025, e69061. https://doi.org/10.2196/69061.

Pino 1

Eniusky Pino

Florida National University

Professor Yvette De la Vega

Advanced Writing and Research-DBX-DL01

19 July 2026

Continuous Glucose Monitoring in Type 2 Diabetes Care

For many adults with type 2 diabetes, glucose monitoring typically involves stopping several times a day to prick a finger and jotting down a single number. Continuous glucose monitoring (CGM) modifies that experience by employing a small sensor worn on the body to measure glucose in the fluid under the skin all day and all night. The sensor delivers information to a receiver or smartphone, allowing patients and clinicians to observe patterns, trends and alerts rather than isolated measurements. CGM was first used mostly by people with type 1 diabetes or those on intensive insulin therapy, but emerging data has broadened its relevance in general care for adults with type 2 diabetes, including some who use basal insulin exclusively or noninsulin medicines. This is especially important for family nurse practitioners, as managing diabetes includes appropriate medication adjustments, patient education, lifestyle counseling, and prevention of complications. Continuous glucose monitoring is reshaping type 2 diabetes care by improving glycemic control, strengthening patient self-management and primary care collaboration, and offering long-term economic value despite ongoing barriers involving cost, training, insurance coverage, and equitable access.

First, CGM can enhance control of blood sugar because it gives a fuller view of glucose variations than occasional finger-stick tests. A standard meter tells you what your glucose level is at a single point in time, whereas CGM shows you the direction and speed of change, time spent in range, bouts of hyperglycemia and probable hypoglycemia. The MOBILE randomized clinical trial included people with poorly controlled type 2 diabetes receiving basal insulin therapy in primary care settings. Investigators found that CGM was associated with “significantly lower HbA1c levels at 8 months” compared to blood glucose meter monitoring (Martens et al. ). This finding is noteworthy because even a moderate drop in HbA1c may assist clinicians determine whether medication, nutrition or activity strategies are working. The wider research backs up the trial findings. In 2024 a comprehensive review and meta-analysis of twelve randomized trials indicated that CGM lowered HbA1c by an average of 0.31 percentage points and increased time in range by more than six percentage points. The authors concluded that “CGM use compared with SMBG is associated with improvements in glycaemic control” (Jancev et al. . The device also picks up overnight and post-meal patterns that patients may not see with planned testing. For the family nurse practitioner, these trends can help to make safer drug modifications and more targeted counseling. CGM data should not replace a clinical assessment. Sensor accuracy, symptoms, medications and the individual’s treatment plan still need to be addressed.

CGM can also enhance self-management and promote collaboration between patients and primary care teams. With diabetes, people have to make daily decisions regarding food, exercise, medicine, sleep and stress, but many patients cannot clearly relate these actions to subsequent glucose results. They get instant feedback and can see how a meal, an exercise or a missing medication alters the glucose curve.” In the DISCO GM randomized crossover study, people with complex type 2 diabetes reported improvement in self-management scores, quality of life, HbA1c and time in range. The researchers found that “the introduction of CGM can significantly improve diabetes self-management behaviour” (Parsons et al.). This instructional impact can make an abstract guideline, like limiting refined carbs, visible and personal. CGM also can increase the efficiency of office visits since the practitioner, and the patient can study the same data and establish specific goals. A 2025 pilot project trained primary care doctors to read CGMs using pharmacists and diabetes educators to help with sensor implantation, teaching and follow-up. Increased time in range significantly and average HbA1c fell from 9.68% to 7.31%. The authors concluded that using CGM in primary care was “feasible and effective using a multidisciplinary approach” (Zadel et al.). These data show that effective implementation is a function not just of acquiring the device, but also of educating patients how to respond to the information and preparing doctors to read the standardized reports . Without education, too many alarms or strange graphs might produce confusion instead of confidence.

Finally, the long-term benefits of CGM should be weighed against the practical and ethical constraints of the device. There is an ongoing cost for sensors and transmitters, and coverage regulations may range depending on insurance plan, prescription regimen and documentation needed. Furthermore, patients may not own a compatible smartphone, have dependable internet access, computer literacy, or the ability to update sensors accurately. But economic research implies that higher monitoring expenses may be compensated by better control and fewer issues. A 2024 U.S. microsimulation of persons with type 2 diabetes on basal insulin found CGM “offered more QALYs … at a lower cost” over 10 years than finger-stick monitoring (Frank et al.). The model estimated savings from decreased severe hypoglycemia events, diabetic ketoacidosis episodes, and long-term cardiovascular and renal consequences. This was a simulation and not a clinical experiment, thus the conclusions are based on the assumptions that were built into the model and should be read with caution. Another concern is access. A evaluation in 2026 found “ongoing inequities by age, race and ethnicity, insurance coverage and care setting” (Villanueva et al.). These disparities may deny people with the greatest illness burden access to technology. Primary care organizations consequently need clear eligibility processes, staff training, appropriate language education, technical support, privacy measures and plans for patients who cannot afford sensors on an ongoing basis. CGM can be a high-value improvement, but without healthcare systems addressing pricing and digital access its advantages will be unequal.

To conclude, continuous glucose monitoring represents an important improvement in the management of type 2 diabetes. Research demonstrates it can enhance HbA1c and time in range, assist patients understand how their daily actions impact glucose, and encourage more focused engagement with family nurse practitioners and interdisciplinary primary care teams. Economic models also imply that avoiding acute events and long-term problems may offset some of the expense of the technology. At the same time, CGM is not necessarily helpful for every patient. Insurance limits, device costs, data interpretation, alarm fatigue, and inequitable access may limit its utility. The most appropriate method is therefore to combine the device with tailored education, clinical follow-up and equal coverage policies. As CGMs become more popular in primary care, family nurse practitioners will be key in identifying who may benefit, training patients how to utilize the information securely, and ensuring that technology improves treatment rather than widens existing gaps.

Works Cited

Frank, Jerry, et al. “Continuous Glucose Monitoring for Self-Management of Diabetes in People Living with Type 2 Diabetes Mellitus on Basal Insulin Therapy: A Microsimulation Model and Cost-Effectiveness Analysis from a US Perspective with Relevance to Medicaid.” Journal of Managed Care & Specialty Pharmacy, vol. 30, no. 9, 2024, pp. 917–928. https://doi.org/10.18553/jmcp.2024.24025.

Jancev, Milena, et al. “Continuous Glucose Monitoring in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.” Diabetologia, vol. 67, no. 5, 2024, pp. 798–810. https://doi.org/10.1007/s00125-024-06107-6.

Martens, Thomas W., et al. “Effect of Continuous Glucose Monitoring on Glycemic Control in Patients with Type 2 Diabetes Treated with Basal Insulin: A Randomized Clinical Trial.” JAMA, vol. 325, no. 22, 2021, pp. 2262–2272. https://doi.org/10.1001/jama.2021.7444.

Parsons, Sharon N., et al. “Does the Short-Term Use of Continuous Glucose Monitoring Enhance Diabetes Self-Management Behaviour in Type 2 Diabetes? The DISCO GM Study: A Randomised, Controlled Cross-Over Study.” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, vol. 19, no. 7, 2025, article 103283. https://doi.org/10.1016/j.dsx.2025.103283.

Villanueva, Giuliana Perini, et al. “Continuous Glucose Monitoring in Type 2 Diabetes: Clinical Outcomes, Disparities in Access, and Cost-Effectiveness.” Current Diabetes Reports, vol. 26, no. 1, 2026, article 19. https://doi.org/10.1007/s11892-026-01631-8.

Zadel, Alyssa H., et al. “Continuous Glucose Monitoring in Primary Care: Multidisciplinary Pilot Implementation Study.” JMIR Diabetes, vol. 10, 2025, e69061. https://doi.org/10.2196/69061.